Preparation of azithromycin nanosuspensions by reactive precipitation method

References

• Dolenc A, Kristl J, Baumgartner S, Planinsek O. (2009). Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm, 376:204–212.
   PubMed Web of Science ®Google Scholar
• Lipinski C. (2002). Poor aqueous solubility, an industry wide problem in drug discovery. Am Pharm Rev, 5:82–85.
   Google Scholar
• Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. (2007). When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci, 31:249–261.
   PubMed Web of Science ®Google Scholar
• Noyes AA, Whitney WR. (1897). The rate of solution of solid substances in their own solutions. J Am Chem Soc, 19:930–934.
   Google Scholar
• Hu J, Johnston KP, Williams RO 3rd. (2004). Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm, 30:233–245.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2011). Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm, 37:243–251.
   PubMed Web of Science ®Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
   PubMed Web of Science ®Google Scholar
• Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T et al. (2005). Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm, 31:319–329.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
   PubMed Web of Science ®Google Scholar
• Bhakay A, Merwade M, Bilgili E, Dave RN. (2011). Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev Ind Pharm, 37:963–976.
   PubMed Web of Science ®Google Scholar
• Verma S, Kumar S, Gokhale R, Burgess DJ. (2011). Physical stability of nanosuspensions: Investigation of the role of stabilizers on Ostwald ripening. Int J Pharm, 406:145–152.
   PubMed Web of Science ®Google Scholar
• Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. (2006). Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir, 22:906–910.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Van den Mooter G, Augustijns P. (2008). Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm, 364:64–75.
   PubMed Web of Science ®Google Scholar
• Ohshima H, Miyagishima A, Kurita T, Makino Y, Iwao Y, Sonobe T et al. (2009). Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution. Int J Pharm, 377:180–184.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev, 58:1688–1713.
   PubMed Web of Science ®Google Scholar
• Chaubal MV, Popescu C. (2008). Conversion of nanosuspensions into dry powders by spray drying: A case study. Pharm Res, 25:2302–2308.
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Hu XM, Yi YM, Wan J. (2009). Preparation and body distribution of freeze-dried powder of ursolic acid phospholipid nanoparticles. Drug Dev Ind Pharm, 35:305–310.
   PubMed Web of Science ®Google Scholar
• Müler RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm, 160:229–237.
   Google Scholar
• Zhang D, Tan T, Gao L, Zhao W, Wang P. (2007). Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm, 33:569–575.
   PubMed Web of Science ®Google Scholar
• Chingunpitak J, Puttipipatkhachorn S, Chavalitshewinkoon-Petmitr P, Tozuka Y, Moribe K, Yamamoto K. (2008). Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev Ind Pharm, 34:314–322.
   PubMed Web of Science ®Google Scholar
• Krause KP, Kayser O, Mäder K, Gust R, Müller RH. (2000). Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm, 196:169–172.
   PubMed Web of Science ®Google Scholar
• Verma S, Gokhale R, Burgess DJ. (2009). A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm, 380:216–222.
   PubMed Web of Science ®Google Scholar
• Kamiya S, Kurita T, Miyagishima A, Arakawa M. (2009). Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols. Drug Dev Ind Pharm, 35:1022–1028.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xia Q, Gu N. (2006). Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm, 32:857–863.
   PubMed Web of Science ®Google Scholar
• Kocbek P, Baumgartner S, Kristl J. (2006). Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm, 312:179–186.
   PubMed Web of Science ®Google Scholar
• Panagiotou T, Mesite SV, Fisher RJ. (2009). Production of norfloxacin nanosuspensions using microfluidics reaction technology through solvent/antisolvent crystallization. Ind Eng Chem Res, 48:1761–1771.
   Web of Science ®Google Scholar
• Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 86:1–12.
   PubMed Web of Science ®Google Scholar
• Niu X, Zou W, Liu C, Zhang N, Fu C. (2009). Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles. Drug Dev Ind Pharm, 35:1375–1383.
   PubMed Web of Science ®Google Scholar
• Yu L. (2001). Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev, 48:27–42.
   PubMed Web of Science ®Google Scholar
• Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP et al. (2008). High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm, 361:177–188.
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 56:827–840.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, Lindahl A. (2011). A formulation comparison between micro- and nanosuspensions: The importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm, 37:185–192.
   PubMed Web of Science ®Google Scholar
• Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. (2002). Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm, 241:73–85.
   PubMed Web of Science ®Google Scholar
• Tolman JA, Williams III RO. (2010) Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm, 36:1–30.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Zheng T, Wang S. (2007). Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm, 33:1332–1339.
   PubMed Web of Science ®Google Scholar